INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Anika Therapeutics and its officers or directors, following a significant drop in the company's stock price after disappointing clinical trial results for its product Hyalofast [1][3]. Group 1: Company Overview - Anika Therapeutics, Inc. is involved in the development of medical products, including Hyalofast, a resorbable hyaluronic acid scaffold for cartilage repair [3]. - The company is publicly traded on NASDAQ under the ticker ANIK [1]. Group 2: Clinical Trial Results - On July 30, 2025, Anika announced topline results from a pivotal clinical trial of Hyalofast, which showed improvements in treated patients but did not meet its pre-specified co-primary endpoints [3]. - The trial's outcomes were affected by a higher dropout rate in the microfracture arm and missed visits during COVID, leading to missing data and a reduced evaluable sample size [3]. - Following the announcement, Anika's stock price fell by $3.06 per share, or 27.42%, closing at $8.10 per share [3]. Group 3: Legal Investigation - Pomerantz LLP is conducting an investigation on behalf of investors regarding potential securities fraud related to Anika's business practices [1]. - The firm has a long history in corporate, securities, and antitrust class litigation, having recovered multimillion-dollar damages for victims of securities fraud [4].